Impact of KIM-1 expression on the advancement of renal failure- A systematic review
DOI:
https://doi.org/10.61841/whkfdk64Keywords:
Renal failure, Kidney injury molecule, serum creatinine.Abstract
One of the major challenges that are being faced by the public healthcare is the renal failure. The suggested ancient clinical biomarkers for this renal failure are the blood urea nitrogen and serum creatinine. But now-a-days these are not considered that sensitive or specific enough as they solely increase significantly after the presence of extensive failure. Therefore there is a need to investigate more of sensitive and specific biomarkers for any type of renal failure is an important factor in nephropathies. Thus specific biomarkers that can help in detecting the injury at the disease starting stage and early diagnosis of these renal diseases would enable better and enhanced therapeutic treatment for the benefit of the individuals in terms of economic and wellbeing. Application of the recent and advanced technologies such as functional genomics, proteomics, and bio fluid profiling has revealed several new molecules that are emerging as predictive biomarkers of renal failure. The most promising and encouraging in current scenario among those include the urinary proteins such as NGAL, KIM-1, and L-FABP (liver-type fatty acid binding protein). Thus keeping all these points in view of the insensitivity and lack of specificity of the traditional and so called gold standard biomarkers the present review focuses on emphasizing the current insights of the novel biomarkers specifically (KIM-1) Kidney Injury Molecule-1. Thus this review gives an insight of the KIM-1 and its expanding evidence as biomarker for early detector in kidney damage and other kidney diseases. It also discusses about the structure, function, detection and signaling pathway.
Downloads
References
1. Steubl D, Block M, Herbst V, Nockher WA, et al. Plasma uromodulin correlates with kidney function and identifies early stages in chronic kidney disease patients. Medicine 2016; 95: 3011.
2. Parikh CR, Thiessen-Philbrook H, Garg AX, et al. TRIBE-AKI Consortium Performance of kidney injury molecule-1 and liver fatty acid-binding protein and combined biomarkers of AKI after cardiac surgery. Clin J Am Soc Nephrol 2013; 8: 1079–1088.
3. De Silva PMCS, Mohammed Abdul KS, Eakanayake EM, et al. Urinary biomarkers KIM-1 and NGAL for detection of chronic kidney disease of uncertain etiology (CKDu) among agricultural communities in Sri Lanka. PLoS Negl Trop Dis 2016; 10: 4979.
4. V Bailly Z, Zhang W, Meier R, Cate M, et al, Shedding of kidney injury molecule-1, a putative adhesion protein involved in renal regeneration. The Journal of Biological Chemistry 2002; 277(42): 39739–39748.
5. Kaplan G, Totsuka A, Thompson P, et al. Identification of a surface glycoprotein on African green monkey kidney cells as a receptor for hepatitis A virus. EMBO J 1996;15: 4282–4296.
6. Ichimura T, Bonventre JV, Bailly V, et al., Kidney injury molecule-1 (KIM-1), a putative epithelial cell adhesionmolecule containing a novel immunoglobulin domain, is up-regulated in renal cells after injury. Journal of Biological Chemistry 1998; 273(7): 4135–4142.
7. Han WK, Alinani A, Wu CL, et al. Human kidney injury molecule-1 is a tissue and urinary tumor marker of renal cell carcinoma. J Am Soc Nephrol. 2005 Apr;16(4):1126-34
8. van Timmeren MM, van den Heuvel M C, Bailly V, et al. Tubular kidney injury molecule-1 (KIM-1) in human renal disease. The Journal of Pathology 2007; 212(2): 209–217.
9. Chimura T, Hung CC, Yang SA, Stevens JL, et al. Kidney injury molecule-1: a tissue and urinary biomarker for nephrotoxicant-induced renal injury. Am J Physiol Renal Physiol 2004; 286: 552–563.
10. Amin RP, Vickers AE, Sistare F, et al. Identification of putative gene based markers of renal toxicity. Environ Health Perspect 2004; 112: 465–79.
11. Zeisberg M, Neilson EG. Mechanisms of tubulointerstitial fibrosis. J. Am. Soc. Nephrol 2010; 21: 1819–1834.
12. Slocum J L, Heung M, Pennathur S. Marking renalinjury: can we move beyond serum creatinine?. Translational Research 2012; 159(4): 277–289.
13. Sabbisetti VS, Ito K, Wang C., et al. Novel assays for detection of urinary KIM-1 in mouse models of kidney injury. Toxicological Sciences 2013; 131(1): 13–25.
14. Kramer AB, van Timmeren MM, Schuurs TA, et al. Reduction of proteinuria in adriamycin-induced nephropathy is associated with reduction of renal kidney injury molecule(Kim-1) over time, American Journal of Physiology—RenalPhysiology 2009; 296(5):1136–1145.
15. Shao X, Xie Y, Wang Q, et al. · Mou S. Kidney Injury Molecule-1 is Elevated in Nephropathy and Mediates Macrophage Activation via the Mapk Signalling Pathway Tian L. · Cell Physiol Biochem. 2017;41(2):769- 783
16. Nickolas TL, O’Rourke MJ, Yang J, et al. Sensitivity and specificity of a single emergency department measurement of urinary neutrophil gelatinase-associated lipocalin for diagnosing acute kidney injury. Ann. Intern. Med 2008; 148: 810–819.
17. van de Vrie M, Deegens JK, van der Vlag J, et al. Effect of long-term storage of urine samples on measurement of kidney injury molecule 1 (KIM-1) and neutrophil gelatinase-associated lipocalin (NGAL). Am J Kidney Dis 2014; 63: 573–576
18. U.S. Food and Drug Administration: FDA, European Medicines Agency to consider additional test results when assessing new drug safety: Collaborative effort by FDA and EMEA expected to yield additional safety data.
19. van de Vrie M, Deegens JK, van der Vlag J, et al.. Effect of long-term storage of urine samples on measurement of kidney injury molecule 1 (KIM-1) and neutrophil gelatinase-associated lipocalin (NGAL). Am J Kidney Dis. 2014; 63: 573–576.
20. Pennemans V, Rigo JM, Penders J, et al. Collection and storage requirements for urinary kidney injury molecule-1 (KIM-1) measurements in humans. Clin Chem Lab Med. 2012; 50: 539–543.
21. Pennemans V, Rigo JM, Faes C, et al. Establishment of reference values for novel urinary biomarkers for renal damage in the healthy population: Are age and gender an issue?. Clin Chem Lab Med 2013; 51:1795–1802.
22. McWilliam SJ, Antoine DJ, Sabbisetti V, et al. Reference intervals for urinary renal injury biomarkers KIM-1 and NGAL in healthy children. Biomark Med. 2014; 8: 1189–1197.
23. Alam, M. SHABBIR, et al. "Effect of khat (Catha edulis) consumption on the functions of liver, kidney and lipid profile in male population of Jazan Region of Kingdom of Saudi Arabia." Inter J Applied Natural Sci 3.2 (2014): 9-14.
24. ARQUEZ, HUMBERTO FERREIRA. "BILATERAL VARIATIONS IN THE BLOOD SUPPLY OF
KIDNEYS." International Journal of Research in Applied, Natural and Social Sciences (IMPACT: IJRANSS)
2.4 (2014):79-84
25. Sharma, Surinder K., Indira R. Samal, and SOUMYA NP. "Urinary Stones in Southern India: Biochemical Analysis and its Clinical Implications." International Journal of General Medicine and Pharmacy (IJGMP) 4.1 (2015): 93-100.
26. SIREESHA, D. MANASA, N. SRIVIDYA, and KVSB VIDYA SAGAR. "A STUDY ON AEROBIC BACTERIAL ISOLATES FROM PATIENTS SUFFERING FROM SYMPTOMATIC URINARY TRACT
INFECTION." International Journal of General Medicine and Pharmacy (IJGMP) 6.4 (2017):1-6
27. Agyeman-Yeboah, J. O. A. N. A., and KWADWO AMEYAW Korsah. "Determinants of clinical utilizations of the nursing process by nurses: a study at the 37 Military Hospital, Accra." International Journal of General Medicine and Pharmacy (IJGMP) 5.6 (2016): 1-23.
28. Abed, ALAA HUSSEIN. "Violence against emergency care staff in Basra hospitals." International journal of medicine and pharmaceutical sciences (IJMPS) 4.2 (2014): 99-110.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
